Main Menu

Human respiratory syncytial virus (RSV) continues to be the leading viral cause of severe acute lower respiratory tract disease in infants and children worldwide. A licensed vaccine or antiviral drug suitable for routine use remains unavailable. This invention relates to the use of murine pneumonia virus (MPV), a virus to which humans normally are not exposed to and that is not cross-protected with RSV, as a vector to express the RSV fusion (F) glycoprotein as an RSV vaccine candidate. The RSV F ORF was codon optimized.

A Loa loa specific antigen that can be used as the basis of an immunoassay for the diagnosis of Loa loa infection.

Ebola virus surveillance in wildlife vectors of infection transmission to humans.

Pneumonia virus of mice expression vector PSynK-PVMJ3666.

Details for this material are provided in the NIH AIDS Reagent Program Catalog (Catalog# 11445): https://www.aidsreagent.org/reagentdetail.cfm?t=expression_vectors&id=210.

Loa loa microfilarial-specific peptide sequences that could be used as a research material as well as for development of immunoassays for detection of Loa loa microfilaremia.

Details for these materials may be found in the NIH AIDS Reagent Program Catalog –

• RSC3 (Catalog# 12042): https://www.aidsreagent.org/reagentdetail.cfm?t=proteins&id=214
• RSC3 delta371I (Catalog# 12043): https://www.aidsreagent.org/reagentdetail.cfm?t=proteins&id=146
• RSC3 delta371I/P363N (Catalog# 12362):

Reagents particularly useful in configuring multiplex assays for simultaneous measurement and quantification of multiple eosinophil granule proteins and for immunohistochemistry. Ultimately these reagents may be used as diagnostics for many eosinophil-mediated disorders.

Human parainfluenza virus (hPIV) is an RNA-based paramyxovirus that causes respiratory infections in children and adults. There are four serotypes that can result in a myriad of diseases of the respiratory tract including croup, bronchitis, and pneumonia (Mao et al., 2012). hPIV is a leading cause of respiratory tract infection and hospitalization among children under 5, only surpassed by the respiratory syncytial virus (RSV). Currently, there are limited treatment options and no approved vaccines.

The VRC01-class of potent, broadly neutralizing antibodies (bnAbs) targets the conserved CD4-binding site (CD4bs) of HIV-1 Env which has been a major target of HIV-vaccine design. The current best priming immunogen to engage the VRC01-class germline precursors is the eOD-GT8 60mer, which elicits VRC01-class precursors in multiple transgenic mouse models. However, a large proportion of the antibodies elicited by eOD-GT8 60mer are non-CD4bs or “off-target” antibodies, undermining its effectiveness in eliciting the VRC01-class bnAb precursors.